Reagents and drugs. MTX and LV were obtained from Lederle Laboratories (Pearl River, N Y ) and TMTX from US Bioscience (West Conshohocken, PA). The fluorescent lysine analog of MTX, Cell lines. The human CCRF-CEM MTX-sensitive ALL parental T-cell line (CEM-S), its MTX-transport resistant subline (CEM-T), and cell lines established from mice bearing CEM-S and CEM-T tumors were propagated in RPM1 1640 supplemented with 10% fetal calf serum, L-glutamine, penicillin, and streptomycin (complete medium) at 37°C and 5% COz.
ECENT STUDIES from this laboratory have indicated that decreased uptake of methotrexate (MTX) is a major mechanism of acquired resistance to MTX in patients with acute lymphoblastic leukemia (ALL) and is present in approximately half of the patients who are clinically resistant to this drug.' Trimetrexate (TMTX), a second-generation folate antagonist now in clinical trial, is still effective against these MTX-transport-resistant cells, because this compound does not use the reduced folate carrier-mediated active transport system for cell entry.2s3 In addition, transport-defective MTX-resistant cells are poorly rescued by leucovorin (LV), a reduced folate that also uses the reduced folate transport system for cell e r~t r y .~.~ In this communication we report studies using MTX-transport-resistant human ALL blasts propagated in severe combined immunodeficiency (SCID) mice as a model system to show that LV may be used to protect the host from TMTX toxicity but not the tumor. Cell lines. The human CCRF-CEM MTX-sensitive ALL parental T-cell line (CEM-S), its MTX-transport resistant subline (CEM-T), and cell lines established from mice bearing CEM-S and CEM-T tumors were propagated in RPM1 1640 supplemented with 10% fetal calf serum, L-glutamine, penicillin, and streptomycin (complete medium) at 37°C and 5% COz.
R MATERIALS AND METHODS

Reagents and drugs. MTX and LV were obtained from Lederle Laboratories (Pearl River
Mice. Pathogen-free C.B-17 scid/scid mice (SCID mice), 6 to 7 weeks old, purchased from Taconic Farm (Germantown, NY), were housed in microisolater cages under specific pathogen-free conditions and received autoclaved food and water.
In vivo studies. SCID mice were inoculated subcutaneously in the right flank with lo7 CEM-T leukemic cells and observed twice weekly for development of tumor formation at the site of inoculation, as previously described.' The dimensions of the nodules and weight of the animals were evaluated before the institution of treatment and three times per week thereafter. Mice were randomized to receive TMTX alone, at a daily dose of 20 mgkg for 5 days, or the combination of TMTX and LV, both administered at a dose of 40 mgkg twice daily for 10 days, once tumors were palpable. A control group did not receive treatment. TMTX and LV were administered intraperitoneally. The mice were killed and autopsied when the tumor mean surface area exceeded 600 m m ' or when the mice were judged to be moribund. Single-cell suspensions from subcutaneous nodules, liver, spleen, thymus, and bone marrow were analyzed by flow cytometry for surface expression of human antigens and by fluorescence in situ hybridization for the detection of human X chromosome. Tumor cells recovered from SCID mice were also studied for sensitivity to MTX and TMTX as well as for their ability to transport MTX by the PT430 competitive displacement assay.
Cytotoxicity assay. In vitro exponentially growing CEM-S and CEM-T leukemic cells and cells recovered from tumor-bearing animals before and after treatment with TMTX or the combination of TMTX plus LV were exposed to various concentrations of MTX or TMTX with and without LV for 72 hours in 96-well plates. To assess cell viability, the reduction of XTI' dye (final concentration, 0.2 mg/mL) with PMS was evaluated after 4 hours of incubation with an EL-340 Biokinetics Reader (Biotek Instruments, Winooski, VT) at a wavelength of 450 nm and 650 nm, as described elsewhere.' PT430 competitive displacement assay. Uptake of MTX by CEM-S and CEM-T leukemic cells, before inoculation and after recovery from SCID mice, was determined by the PT430 competitive displacement assay, as previously described.' Briefly, aliquots of 5 X lo6 cells were incubated with 2 pmol/L PT430 for 2 hours at 37"C, after which they were washed three times in phosphate-buffered saline (PBS), incubated at 37°C for 30 minutes in complete medium to allow for efflux of exchangeable PT430, washed twice in PBS, resuspended in competitive displacement buffer, and incubated with MTX for 2 hours at 37°C and 5% CO2. Thereafter, the cells were washed twice in PBS to remove displaced FT430 and analyzed by flow cytometxy. Mean fluorescence intensity was measured and percent displacement of PT430 by MTX uptake was calculated as mean peak fluorescence decrease. Flow cytornetry. In vitro cultured cell lines and leukemic cells recovered from SCID mice inoculated with the same cell lines were stained with monoclonal antibodies directed against human CD45, CD2, CD3, CD7, CD4, CD8, CD25 (interleukin-2 receptor LY chain [TACJ), CD71, and HLA-DR conjugated either with fluorescein isothyocyanate (FITC) or phycoerythrin (Becton Dickinson, San Jose, CA). Mouse cells were detected by antimouse CD45 FITCconjugated monoclonal antibody (Boehringer Mannhein, Indianapolis, IN). The cells were prepared following standard protocols, which have been already described? A FACS scan flow cytometer using LYSIS I1 software (Becton Dickinson, Sunnyvalle, CA) was used for analysis of surface antigen expression and for the PT430 competitive displacement assay.','
Statistical analysis. The Wilcoxon rank-sum test was used to compare the decrease in tumor mean surface area from day 28 to day 42 in both groups of treated mice (TMTX and TMTX-LV) relative to the group of untreated animals.
RESULTS
Cytotoxicity studies. In vitro growing CEM-S and CEM-T cells and those recovered from subcutaneous tumors of untreated mice were exposed for 72 hours to various concentrations of MTX, after which growth inhibition was assessed by XTT reduction with PMS (see Materials and Methods). As depicted in Fig 1, the ICso of MTX was 15-fold higher for CEM-T than for CEM-S cells. CEM-S and CEM-T cells recovered from untreated SCID mice had the same sensitivity to MTX as the original cell lines (Fig 1) . The MTXtransport-defective CEM-T cell line was more sensitive to TMTX than the parental, MTX-sensitive CEM-S cell line (Fig 2A and B) . At low concentrations of LV, CEM-T cells were not protected from TMTX cytotoxicity and higher concentrations of LV were able to only partly protect this cell line (Fig 2B) . In contrast, LV protected CEM-S cells to a much greater degree than CEM-T cells for all the concentrations of LV tested (Fig 2A) .
PT430 competitive displacement assay. We have previously shown that the PT430 competitive displacement assay can accurately distinguish the capacity of CEM-S and CEM-T cells to transport MTX.' No differences in MTX uptake were found between the original cell lines and those recovered from untreated SCID mice. As depicted in Fig 3, there was marked displacement of the MTX-lysine analog, PT430, in CEM-S cells recovered from untreated SCID mice after incubation with MTX (Fig 3A) . In contrast, there was virtually no PT430 displacement by MTX in untreated CEM-T cells (Fig 3B) . original cells (data not shown). In a preliminary experiment, mice inoculated with CEM-T cells (n = 6) and CEM-S cells (n = 6) were randomized at day 28 not to be treated (n = 3, each cell line) or to receive the combination of TMTX plus LV (n = 3, each cell line). There were tumor regressions only in mice inoculated with CEM-T cells and treated with the combination of TMTX and LV, whereas untreated CEM-T mice and those bearing CEM-S tumors (treated and untreated) did not respond to this treatment and had progressive growth of leukemic tumors (data not shown). In a second experiment shown in Fig 4, 18 mice bearing CEM-T tumors were randomized into three groups of 6 mice. The control group received no treatment (Fig 4A) , a second group received TMTX alone (Fig 4B) , and the third group received TMTX and LV (Fig 4C) . Both groups of treated mice had complete tumor regression (P < .001 for both). The animals that received TMTX alone had complete regression of leukemic tumors after the last day of treatment (day 33), whereas mice that received the combination of TMTX and LV did not have palpable tumors after 8 days of treatment (day 36).
Five of six mice in each treatment group had regrowth of tumors by day 56 (Fig 4B and C) and did not respond to a second course of TMTX plus LV. Both treatment regimens produced minimal weight loss (<2 g). For TMTX cytotoxicity in CEM-T cells recovered from treated animals with the addition of 1 pmol/L LV (Fig 5B) .
Resistance mechanisms in CEM-T cells afer treatment in vivo with
One possible explanation for these results was that TMTXresistant cells had been selected and were now capable of transporting LV, being protected from TMTX cytotoxicity. CEM-T cells recovered from animals treated with TMTX and LV were now completely sensitive to MTX (Fig 6) ; ie, this regimen has selected revertants, presumably now able to transport MTX as well as LV. Tumors from animals treated with TMTX alone were partially sensitive to MTX (Fig 6) . The sensitivity profile shows that there may be two populations of cells, with the minor population still showing increased resistance to MTX (Fig 6) . To confirm that TMTX and LV-treated CEM-T cells were now sensitive to MTX as a consequence of selection of transport revertants, the PT430 displacement assay to evaluate MTX uptake was repeated. As depicted in Fig 7, MTX was capable of displacing intracellular PT430 in CEM-T cells recovered from mice treated with TMTX plus LV to the same degree as in CEM-S cells (Fig 3A) , showing that these TMTX-LV-treated CEM-T cells were able to now transport MTX.
DISCUSSION
The CEM-T cell line is 15-to 20-fold resistant to MTX as a result of impaired MTX uptake." As shown in Fig  3A) .
For personal use only. on September 24, 2017. by guest www.bloodjournal.org From these cells grow readily in SCID mice; with the inoculation of lo7 cells, the tumor take was 100%. We used this model system to test the concept that LV would increase the therapeutic index of TMTX by decreasing host toxicity, without compromising antitumor efficacy. TMTX alone was highly effective in the treatment of this tumor, both in vitro and in CEM-T-inoculated SCID mice. However, in the clinic, two trials with TMTX as treatment for relapsed ALL showed only transient activity, because TMTX dosage was limited due to severe
We used a dose of TMTX in mice equivalent to the doses used in humans to treat pneumocystis carinii infection, in combination with LV.13 This pathogen, similar to transportresistant ALL blasts, is unable to transport LV; thus, LV does not protect this organism from TMTX lethal effects.14 In patients with pneumocystis carinii infection, this dose schedule has been shown to be well tolerated and highly effecti~e.'~ In mice, this dose schedule of TMTX (40 mgkg or 120 mg/m2 twice daily for 10 days) is an LDlW without LV protection"; with LV protection there was little or no toxicity observed (weight loss), with complete tumor regression. The dose of TMTX alone used (20 mg/kg/d for 5 days) is the MTD in mice." As expected, with single-agent treatment of tumor masses of up to 600 m m 3 (consisting of approximately 6 X 10' cells), 5 of 6 mice in each treatment group had tumor regrowth and cure was limited by the emergence of drug resistance. Two mice from each treatment group received a second course of TMTX and LV with minimal response. Of interest, leukemic cells studied after TMTX treatment had regained sensitivity to MTX (Fig 6) , as well as the ability to transport MTX and reduced folates. As expected, these tumor cells were now protected from TMTX cytotoxicity by LV.
The ultimate role of this treatment in patients with MTXtransport-defective malignancies would probably be in combination with other drugs. This would be relatively easy to accomplish because of the lack of toxicity of the TMTX-LV combination. The sequential use of TMTX-LV followed by MTX to eliminate TMTX-LV resistant cells may also be a worthwhile approach. We are currently also exploring the use of this regimen in SCID mice bearing fresh tumor cells from MTX-resistant ALL patients and in other tumors that are defective in retention of MTX, either because of decreased influx or as a consequence of lack of MTX polyglutamylation, a major cause of intrinsic resistance in human mdignancies. 16 
